Early Insulin Use in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
It is generally recognized that type 2 diabetes is one of the major challenges of the 21st century. Its prevalence is growing rapidly worldwide, particularly in developing countries (1). It remains the first cause of blindness, end-stage renal disease, and nontraumatic lower-limb amputation and one of the major causes of cardiovascular disease (2,3). Because of its high morbidity and excess mortality, it has become a tremendous burden on health care cost (4). In the last decade, a number of interventions have been shown to be effective in the prevention of diabetes in high-risk populations with impaired glucose tolerance and/or impaired fasting glucose (5–7). Yet, few countries have adopted policies for the screening and strategies for treating subjects with pre-diabetes. Furthermore, despite the development of newer therapies for treatment of diabetes, the disease is still associated with a high incidence of microangiopathy and macrovascular complications. Any new strategies that could help to curtail the burden of diabetes would be greatly appreciated. More recently, it was postulated that early insulin replacement in type 2 diabetes, and perhaps even in pre-diabetes, may reduce cardiovascular risk and may even offer protection for the β-cell (8,9). However, a closer look at the available data does not support the hypothesis. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study is still ongoing and therefore does not allow any conclusion in pre-diabetes. In type 2 diabetes, however, the published data support neither a beneficial effect of insulin therapy per se on microvascular complications, nor on cardiovascular events and mortality. In addition, the data suggesting that insulin therapy can improve the β-cell response to a glucose challenge could just as well be interpreted as being due to the improvement in glycemic control, rather than to the insulin therapy. And finally, …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Changes in blood glucose (BG) and plasma insulin (immunoreactive insulin [IRI]) during a 100-g glucose tolerance test before and after treatment with diet only, sulfonylurea (SU), or insulin of overtly diabetic patients (mean ± SD) according to the initial sum of blood glucose. Number in parentheses indicates number of patients before treatment (●) and after treatment (○). Reproduced with permission from Kosaka et al. (21).](https://figures.cochat.ai/paper-figures/1a7c66febb88468ca7b9937adbb6af13/early-insulin-use-in-type-2-diabetes-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin therapy, in the form of multiple daily subcutaneous injections, is effective at lowering plasma glucose levels and is usually required in the majority of patients when the aforementioned treatment regimens fail, but there are several side effects, such as weight gain, hypoglycaemia and increased risk of colorectal cancer.3,244”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [244]
In the citing paper
“Insulin therapy, in the form of multiple daily subcutaneous injections, is effective at lowering plasma glucose levels and is usually required in the majority of patients when the aforementioned treatment regimens fail, but there are several side effects, such as weight gain, hypoglycaemia and increased risk of colorectal cancer.3,244”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [244]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Gordon-Dseagu, V., Shelton, N. J., & Mindell, J. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27703 · Cited by 57
The expanded human disease network combining protein–protein interaction information
Zhang, X., Zhang, R., Jiang, Y., Sun, P. G., Tang, G., Wang, X., Lv, H., & Li, X. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.30 · Cited by 57
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 49
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
Short‐term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps
Weng, J., Retnakaran, R. R., Ammini Ariachery, C., Ji, L., Meneghini, L., Yang, W., & Woo, J. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2603 · Cited by 25
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
The role of the nurse practitioner in the diagnosis and early management of type 2 diabetes
Robertson, C. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00719.x · Cited by 31
Abu-Ashour, W., Chibrikova, L., Midodzi, W. K., Twells, L., & Gamble, J. (2016) · Diabetic Medicine · doi:10.1111/dme.13082 · Cited by 21
The role of insulin resistance in experimental diabetic retinopathy—Genetic and molecular aspects
Järgen, P., Dietrich, A., Herling, A. W., Hammes, H., & Wohlfart, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178658 · Cited by 19
Mohamad, M. R., Moussally, K., Lakis, C., El-Hajj, M., Bahous, S. A., Peruzzo, C., Reid, A. J. S., & Edwards, J. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251316 · Cited by 19
Khan, N. M., Ahmad, A., Tiwari, R., Kamal, M. A., Mushtaq, G., & Ashraf, G. M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023160448 · Cited by 20
Zargoush, M., Ghazalbash, S., Hosseini, M. M., Alemi, F., & Perri, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-12310-1 · Cited by 13
Grandl, G., Colldén, G., Feng, J. B., Bhattacharya, S., Klingelhuber, F., Schomann, L., Bilekova, S., Ansarullah, M., Xu, W., Far, F. F., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00991-3 · Cited by 12
Lu, C., Chen, Y., Chen, S., Hsu, Y., Lin, C., Tsao, J.-W., Juan, Y., Yang, J., & Tsai, F. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6152 · Cited by 9
A comparative drug utilisation study of the treatment of diabetes in Malaysia and Australia
Hassan, S., Clavarino, A. M., Mamun, A. A., & Kairuz, T. E. (2015) · Australasian Medical Journal · doi:10.4066/amj.2015.2330 · Cited by 8
Hanefeld, M., Fleischmann, H., Liebl, A., & Siegmund, T. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0820-1665 · Cited by 3
Long Term Evaluation of Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus
MERCADO-ASIS, L. B. (2021) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv2i3002 · Cited by 2
Patient-adjusted versus health professional-adjusted insulin dosing for type 2 diabetes mellitus
Ng, C. J., Liew, S. M., Vethakkan, S. R., Abdullah, A. B., & Teng, C. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010574
RetractedLetter: The Association between Type 2 Diabetes Mellitus and Colorectal Cancer
Chung, H.-K. (2011) · Endocrinology and Metabolism · doi:10.3803/enm.2011.26.4.364
Biphasic Insulin Analogs for Treatment of Diabetes: A Review
(2011) · The Internet Journal of Family Practice · doi:10.5580/d20
Short‐Term Intensive Insulin Therapy in Patients with Newly Presenting Type 2 Diabetes
Xu, W., Owens, D. R., & Weng, J. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch33
Signalling and Regulation of the Glucagon-like Peptide-1 receptor
Lu, J. N. (2014) · Figshare
Metadata
- Authors
- Chiasson, J.-L.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Chiasson, Jean-Louis
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S270-S274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811465
- OpenAlex
- W2108706134
- Cited by
- 24
- References
- 31
- Citations by year
- 2025: 1 · 2024: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, early insulin therapy, insulin replacement therapy, prediabetes, impaired glucose tolerance, impaired fasting glucose, cardiovascular risk, microvascular complications, beta-cell function, ORIGIN trial, glycemic control, diabetes prevention
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Microcirculation, Risk, Sulfonylurea Compounds, Colorectal Neoplasms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.